Co. Cork

Aug 16, 2024 | jdscommun.org | Co. Cork

Methane emissions from enteric fermentation account for the majority of greenhouse gas emissions from dairy production systems in Ireland (EPA, 2023). Feed additives provide a solution to reduce enteric CH4 output (Beauchemin et al., 2022). At present, 3-NOP (Bovaer10®; 10% 3-NOP on carrier) is one of the most promising anti-methanogenic feed additives internationally (Beauchemin et al., 2022), with reductions in CH4 of 33% reported when offered within TMR and PMR diets (Kebreab et al., 2023).

Mar 27, 2024 | bmcmicrobiol.biomedcentral.com | R. Paul |APC Microbiome Ireland |College Rd |Co. Cork

Vancomycin-resistant enterococci often represent multi-drug resistance strains and pose a recurring and lethal risk to patients in healthcare facilities. Hypermutable enterococci of clinical interest, such as Enterococcus faecium, often lack CRISPR systems, resulting in the promiscuous acquisition of exogenous DNA and the ability to mutate and persist in challenging niches, such as the healthcare setting.

Mar 19, 2024 | academic.oup.com | Luke Byrne |Co. Cork |Mb Mrcpi

Accepted manuscripts are PDF versions of the author’s final manuscript, as accepted for publication by the journal but prior to copyediting or typesetting. They can be cited using the author(s), article title, journal title, year of online publication, and DOI. They will be replaced by the final typeset articles, which may therefore contain changes. The DOI will remain the same throughout.

Jan 31, 2024 | medicalindependent.ie | Co. Cork

GP wanted for vibrant ICGP training practice in Youghal. Youghal is a beautiful seaside town with growing population and economy. Easy commute from Cork, South Tipperary and West Waterford. Excellent long term career prospects in a thriving practice. We are flexible and interested in meeting with all interested parties. Competitive rates offered with indemnity Medical Council and other subscriptions paid by the practiceFive weeks annual leave (pro rata). Sessions/days or full week considered.

Jan 16, 2024 | rxlist.com | Co. Cork

WARNING SERIOUS INFECTIONS and MALIGNANCY SERIOUS INFECTIONS Patients treated with infliximab products are at increased risk for developing serious infections that may lead to hospitalization or death [see WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS]. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. IXIFI™ should be discontinued if a patient develops a serious infection or sepsis.